Literature DB >> 19295199

Calcium and phosphate control by dialysis treatments.

Piergiorgio Messa1, Roberta Cerutti, Brigida Brezzi, Carlo Alfieri, Mario Cozzolino.   

Abstract

Calcium and phosphate changes, besides their involvement in bone disease, have been claimed to also be involved in the increased vascular morbidity and mortality of dialysis patients. Even after the recent advances of therapeutic options, their control still remains a challenging problem. Dialysis treatment is a basic approach to the control of these two electrolytes. Calcium control by dialysis is mainly dependent on its mass balance, which is variably influenced by the calcium concentration difference between blood and dialysis solutions (either dialysate or infusion fluids) and by the duration of the treatment. There is no full agreement on the ideal calcium concentration in dialysis fluids, since this choice is also mostly influenced by the concomitant medical therapy. However, there is some consensus in suggesting a lower calcium concentration in standard hemodialysis (HD) treatment (1.25-1.50 mmol/l) than in dialysis treatments characterized by high convective transport. In peritoneal dialysis, calcium balance is affected by its blood dialysate concentration difference and dialysate glucose concentration, with ideal calcium concentration probably being >1.25 and <1.75 (which are the most commonly used concentrations). Phosphate dialysis balance is also a critical and challenging problem, since the possibility to reach an always desired null or possibly negative balance relies on this. Even though some increased phosphate removal can be obtained with the highest efficiency techniques, such as hemodiafiltration as compared with traditional HD, the most impacting factor still remains the duration of dialysis treatment. However, some experimental attempts at increasing phosphate removal independently of increasing dialysis duration are mentioned. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295199     DOI: 10.1159/000209249

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  4 in total

Review 1.  Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.

Authors:  A Galassi; A Cupisti; A Santoro; M Cozzolino
Journal:  J Nephrol       Date:  2014-09-23       Impact factor: 3.902

2.  Phosphate clearance in peritoneal dialysis.

Authors:  Malgorzata Debowska; Rafael Gomez; Joyce Pinto; Jacek Waniewski; Bengt Lindholm
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

3.  Bone Effect and Safety of One-Year Denosumab Therapy in a Cohort of Renal Transplanted Patients: An Observational Monocentric Study.

Authors:  Carlo Alfieri; Valentina Binda; Silvia Malvica; Donata Cresseri; Mariarosaria Campise; Maria Teresa Gandolfo; Anna Regalia; Deborah Mattinzoli; Silvia Armelloni; Evaldo Favi; Paolo Molinari; Piergiorgio Messa
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

4.  Quantification of Dialytic Removal and Extracellular Calcium Mass Balance during a Weekly Cycle of Hemodialysis.

Authors:  Jacek Waniewski; Malgorzata Debowska; Alicja Wojcik-Zaluska; Andrzej Ksiazek; Wojciech Zaluska
Journal:  PLoS One       Date:  2016-04-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.